Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Sasha ThomsonLouis EverestNoah WitzkeTina JiaoSeanthel Delos SantosVivian NguyenMatthew C CheungKelvin Kar-Wing ChanPublished in: Cancer medicine (2021)
Oncology drug indications with higher clinical benefit do not appear to be reimbursed faster than those with low clinical benefit. This suggests the need to prioritize oncology drug indications based on clinical benefit to ensure quicker access to oncology drugs with the greatest benefits.